Log in
Enquire now

List of Nuvation Bio patents

List of Nuvation Bio patents
List of Presidio Pharmaceuticals patents
List of Drexel University patents
List of FIS (company) patents
Founders educated at University of Strathclyde
List of companies in Acero Capital's investment portfolio
Patents where
Current Assignee
Name
is
Nuvation BioNuvation Bio
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 11028058 Heterocyclic compounds as adenosine antagonists

Patent 11028058 was granted and assigned to Nuvation Bio on June, 2021 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11028058
June 8, 2021
‌
US Patent 11306071 Heterocyclic compounds as adenosine antagonists

Patent 11306071 was granted and assigned to Nuvation Bio on April, 2022 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11306071
April 19, 2022
‌
US Patent 11292782 Diarylhydantoin compounds and methods of use thereof

Patent 11292782 was granted and assigned to Nuvation Bio on April, 2022 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11292782
April 5, 2022
‌
US Patent 11254670 1,8-naphthyridinone compounds and uses thereof

Patent 11254670 was granted and assigned to Nuvation Bio on February, 2022 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11254670
February 22, 2022
‌
US Patent 11034669 Pyrrole and pyrazole compounds and methods of use thereof

Patent 11034669 was granted and assigned to Nuvation Bio on June, 2021 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11034669
June 15, 2021
‌
US Patent 10793561 1,8-naphthyridinone compounds and uses thereof

Patent 10793561 was granted and assigned to Nuvation Bio on October, 2020 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
10793561
October 6, 2020
‌
US Patent 11299493 Heterocyclic compounds and uses thereof

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11299493
April 12, 2022
‌
US Patent 11332473 Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors

Patent 11332473 was granted and assigned to Nuvation Bio on May, 2022 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11332473
May 17, 2022
‌
US Patent 11174252 Heterocyclic compounds as kinase inhibitors

Patent 11174252 was granted and assigned to Nuvation Bio on November, 2021 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11174252
November 16, 2021
‌
US Patent 11192900 Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors

Patent 11192900 was granted and assigned to Nuvation Bio on December, 2021 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11192900
December 7, 2021
‌
US Patent 10807994 Heterocyclic compounds and uses thereof

Patent 10807994 was granted and assigned to Nuvation Bio on October, 2020 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
10807994
October 20, 2020
‌
US Patent 11834458 Anti-cancer nuclear hormone receptor-targeting compounds

Patent 11834458 was granted and assigned to Nuvation Bio on December, 2023 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11834458
December 5, 2023
‌
US Patent 12006314 Anti-cancer nuclear hormone receptor-targeting compounds

Patent 12006314 was granted and assigned to Nuvation Bio on June, 2024 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
12006314
June 11, 2024
‌
US Patent 11952349 Anti-cancer nuclear hormone receptor-targeting compounds

Patent 11952349 was granted and assigned to Nuvation Bio on April, 2024 by the United States Patent and Trademark Office.

Nuvation Bio
Nuvation Bio
Nuvation Bio
Nuvation Bio
United States Patent and Trademark Office
United States Patent and Trademark Office
11952349
April 9, 2024
14 results
0 selected
14 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us